Eric Hsu
2024
In 2024, Eric Hsu earned a total compensation of $322.5K as Senior Vice President, Preclinical Research & Development at InMed Pharmaceuticals, a 24% increase compared to previous year.
Compensation breakdown
| Bonus | $45,700 |
|---|---|
| Option Awards | $15,800 |
| Salary | $261,000 |
| Total | $322,500 |
Hsu received $261K in salary, accounting for 81% of the total pay in 2024.
Hsu also received $45.7K in bonus and $15.8K in option awards.
Rankings
In 2024, Eric Hsu's compensation ranked 161st out of 207 executives tracked by ExecPay. In other words, Hsu earned more than 22.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 161 out of 207 | 22nd |
Division Manufacturing | 65 out of 89 | 27th |
Major group Chemicals And Allied Products | 29 out of 36 | 19th |
Industry group Drugs | 29 out of 33 | 12th |
Industry Pharmaceutical Preparations | 27 out of 30 | 10th |
Source: SEC filing on October 28, 2024.
Hsu's colleagues
We found five more compensation records of executives working with Eric Hsu at InMed Pharmaceuticals in 2024.
2024
Eric Adams
InMed Pharmaceuticals
Chief Executive Officer
2024
Michael Woudenberg
InMed Pharmaceuticals
Chief Operating Officer
2024
Alexandra Mancini
InMed Pharmaceuticals
Senior Vice President, Clinical & Regulatory Affairs
2024
Netta Jagpal
InMed Pharmaceuticals
Chief Financial Officer
2024
Jonathan Tegge
InMed Pharmaceuticals
Chief Financial Officer
News
InMed Pharmaceuticals CEO Eric Adams' 2024 pay rises 13% to $415K
October 28, 2024
InMed Pharmaceuticals CEO Eric Adams' 2023 pay falls 22% to $368K
October 27, 2023
InMed Pharmaceuticals CEO Eric Adams' 2022 pay falls 36% to $468K
October 28, 2022
InMed Pharmaceuticals CEO Eric Adams' 2021 pay jumps 73% to $735K
October 28, 2021